Literature DB >> 15829155

Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity.

Dali Yin1, Norihiko Tamaki, Andrew D Parent, John H Zhang.   

Abstract

AIMS: In a variety of tumors, the susceptibility of the tumor cells to apoptotic cell death following chemotherapy is a major determinant of therapeutic outcome. Gliomas are resistant to most chemotherapeutic agents, and its mechanism is not known in detail. In an attempt to understand the mechanism of chemo-resistance, we investigated the roles of insulin-like growth factor-I (IGF-I), IGF-I receptors (IGF-IR), and their relationship with the apoptotic response of two glioma cell lines to etoposide, a chemotherapeutic agent for malignant gliomas.
METHODS: Two human glioma cell lines, U-87MG and KNS-42, were used. Etoposide-induced cell growth inhibition was quantified using a modified MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), colorimetric assay. Hoechst 33258 staining, DNA fragmentation assay, and western blot were used for the evaluation of apoptosis. ApoAlert caspase assay was used for measuring the activity of caspase-3 (CPP32) and interleukin-1 beta -converting enzyme (ICE) protease. In addition, the effect of IGF-IR antisense was tested in U-87MG and KNS-42 glioma cell lines.
RESULTS: Etoposide inhibited the growth of U-87MG and KNS-42 cells in a concentration-dependent manner. Etoposide increased the expression of wild-type p53, activated CPP32 (but not ICE) activity, and induced apoptosis in these cells. IGF-I prevented etoposide-induced apoptosis by increasing the expression of bcl-2 and decreasing the activity of CPP32. IGF-IR antisense enhanced the apoptotic effect of etoposide.
CONCLUSIONS: IGF-I decreased etoposide-induced apoptosis in glioma cells by increasing the expression of bcl-2 and decreasing the activity of CPP32. The antisense of IGF-IR increased etoposide-induced apoptosis. The anti-apoptotic effect of IGF-I and IGF-IR might be related to the chemo-resistance of glioma to chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15829155     DOI: 10.1179/016164105X18151

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  12 in total

Review 1.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

2.  Growth factor receptors signaling in glioblastoma cells: therapeutic implications.

Authors:  Mia Carapancea; Oana Alexandru; Ani S Fetea; Laura Dragutescu; Juan Castro; Ada Georgescu; A Popa-Wagner; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2008-11-30       Impact factor: 4.130

3.  HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

Authors:  Paul Haluska; Joan M Carboni; Cynthia TenEyck; Ricardo M Attar; Xiaonan Hou; Chunrong Yu; Malvika Sagar; Tai W Wong; Marco M Gottardis; Charles Erlichman
Journal:  Mol Cancer Ther       Date:  2008-09-02       Impact factor: 6.261

4.  Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.

Authors:  Paul Haluska; Frank Worden; David Olmos; Donghua Yin; David Schteingart; Gretchen N Batzel; M Luisa Paccagnella; Johann S de Bono; Antonio Gualberto; Gary D Hammer
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-02       Impact factor: 3.333

Review 5.  Molecular biology of head and neck cancer: risks and pathways.

Authors:  Michael E Stadler; Mihir R Patel; Marion E Couch; David Neil Hayes
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

6.  Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.

Authors:  Chandra M Das; Dolly Aguilera; Hernan Vasquez; Preethi Prasad; Ming Zhang; Johannes E Wolff; Vidya Gopalakrishnan
Journal:  J Neurooncol       Date:  2007-05-30       Impact factor: 4.130

7.  The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

Authors:  L R Molife; P C Fong; L Paccagnella; A H M Reid; H M Shaw; L Vidal; H-T Arkenau; V Karavasilis; T A Yap; D Olmos; J Spicer; S Postel-Vinay; D Yin; A Lipton; L Demers; K Leitzel; A Gualberto; J S de Bono
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

8.  Context Sensitive Modeling of Cancer Drug Sensitivity.

Authors:  Bo-Juen Chen; Oren Litvin; Lyle Ungar; Dana Pe'er
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

9.  Trichinella spiralis: nurse cell formation with emphasis on analogy to muscle cell repair.

Authors:  Zhiliang Wu; Lj Sofronic-Milosavljevic; Isao Nagano; Yuzo Takahashi
Journal:  Parasit Vectors       Date:  2008-08-19       Impact factor: 3.876

10.  Obesity and Risk for Brain/CNS Tumors, Gliomas and Meningiomas: A Meta-Analysis.

Authors:  Theodoros N Sergentanis; Georgios Tsivgoulis; Christina Perlepe; Ioannis Ntanasis-Stathopoulos; Ioannis-Georgios Tzanninis; Ioannis N Sergentanis; Theodora Psaltopoulou
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.